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Background: The revolution in DNA sequencing technologies over the past decade has made it feasible to
sequence an individual’s whole genome at a relatively low cost. The potential value of the information generated
by genomic technologies for medicine and society is enormous. However, in order for exome sequencing, and
eventually whole genome sequencing, to be implemented clinically, a number of major challenges need to be
overcome. For instance, obtaining meaningful informed-consent, managing incidental findings and the great
volume of data generated (including multiple findings with uncertain clinical significance), re-interpreting the
genomic data and providing additional counselling to patients as genetic knowledge evolves are issues that need
to be addressed. It appears that medical genetics is shifting from the present “phenotype-first” medical model to a
“data-first” model which leads to multiple complexities.
Discussion: This manuscript discusses the different challenges associated with integrating genomic technologies
into clinical practice and describes a “phenotype-first” approach, namely, “Individualized Mutation-weighed
Phenotype Search”, and its benefits. The proposed approach allows for a more efficient prioritization of the genes
to be tested in a clinical lab based on both the patient’s phenotype and his/her entire genomic data. It simplifies
“informed-consent” for clinical use of genomic technologies and helps to protect the patient’s autonomy and
privacy. Overall, this approach could potentially render widespread use of genomic technologies, in the immediate
future, practical, ethical and clinically useful.
Summary: The “Individualized Mutation-weighed Phenotype Search” approach allows for an incremental
integration of genomic technologies into clinical practice. It ensures that we do not over-medicalize genomic data
but, rather, continue our current medical model which is based on serving the patient’s concerns. Service should
not be solely driven by technology but rather by the medical needs and the extent to which a technology can be
safely and effectively utilized.
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The revolution in DNA sequencing technologies over
the past decade has made it feasible to sequence an indi-
vidual’s whole genome at a relatively low cost [1], [2].
The potential value of the information generated by gen-
omic technologies for medicine and society is enormous.
However, personal genomic testing may not be ready for
widespread clinical use [3]. Analysis, interpretation and
management of the data generated from exome sequen-
cing (ES), which targets slightly more than 1% of the en-
tire genome, have already proven to be a challenge inCorrespondence: :john.trakadis@mail.mcgill.ca
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reproduction in any medium, provided the orthe research context for mendelian disorders [4]. One
can only imagine the level of complexity that will result
from trying to incorporate whole genome sequencing
(WGS) into clinical practice, especially in dealing with
common diseases characterized by complex inheritance.
Nonetheless, the low cost of WGS may encourage its
early adoption creating “a million dollar headache” [5].
First, the extent to which it is possible to obtain mean-
ingful patient informed-consent to large-scale genomic
analysis has been called into question [6], [7]. For in-
stance, genomic approaches increase the chance of
discovering incidental findings or results with uncer-
tain clinical significance. Mutations with incomplete
penetrance, mutations in novel genes with unknownThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Challenges of integrating ES/WGS in clinical
practice
Meaningful patient informed-consent may not be feasible
Complex medical and social implications of the test results,
Possibility of incidental findings,
Multiple findings of uncertain clinical significance,
Insurance companies do not reimburse pre-testing counselling for ES/WGS
Multiple issues to discuss leading to prohibitive requirements in time &
resources
Potential emotional distress over disease risk even among healthy
individuals
Genomic information is a powerful personal identifier
Raising concerns about privacy, confidentiality, genetic discrimination
Very large amounts of genetic information generated
Limited number of clinical geneticists for data interpretation and clinical
care
Substantial time and cost for data analysis and genetic counselling
Dynamic/evolving nature of the interpretation as new knowledge is gained
Duty to re-contact patients as knowledge changes over time
Shift from the present “phenotype-first” medical model to a “data-
first” model.
Currently, genetic risk assessment is restricted to individuals at increased risk
based on family history or clinical presentation (ensuring the necessary
genomic background), or newborn screening programs meeting specific
criteria.
Can we predict the impact of even known pathogenic variants outside this
setting?
Is there adequate evidence to suggest that a departure from these
standards will be beneficial to society?
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increases in disease risk are typical challenging exam-
ples. This information is difficult to conceptualize and
can generate emotional distress over disease risk even
among healthy individuals [8]. Hence, during counsel-
ling, the potential benefits for individuals need to be
weighed against the potential harm and the individuals’
right not to know.
Currently, genetic risk assessment is restricted to indi-
viduals at increased risk based on family history or clin-
ical presentation, which may be indirectly ensuring the
necessary genomic background for the pathogenic role
of a variant. Recent reports suggest that on average, each
person is heterozygous for approximately 50–100 var-
iants classified by the Human Gene Mutation Database
(HGMD) as causing inherited disorders and of approxi-
mately 250 to 300 loss of function variants in annotated
genes [9]. With what degree of certainty can we predict
the impact of even known pathogenic variants when
they are identified as incidental findings [10], [11]?
Moreover, data from personal genome sequencing is a
powerful personal identifier challenging the traditional
mechanisms of protection. This raises concerns about
privacy, confidentiality and potential genetic discrimin-
ation [12].
Responsibly managing the very large amounts of gen-
etic information produced is another key challenge to
overcome [13]. As stated above, the significance of the
data generated from ES/WGS varies from clearly clinic-
ally relevant (e.g. “pathogenic mutations”) to data of un-
known clinical significance (“variants of unknown
significance”, VUS). The evaluation and management of
novel variants identified using ES/WGS require substan-
tial time and cost. Expertise is needed for analysis of the
complex genomic data but there are not enough clinical
geneticists to interpret results from wide-spread whole-
genome sequencing and to provide follow-up informa-
tion and clinical care [14,15]. Moreover, return of
genomic results requires substantial financial resources
for genetic counselling of patients, particularly in the
context of the dynamic, continuously evolving, nature of
the interpretation of ES/WGS results [16]. The practical
challenge of the duty to re-contact patients as know-
ledge changes over time is already experienced in med-
ical genetics secondary to the clinical implementation of
array-comparative genomic hybridization (array CGH)
and research studies using ES. This will be exponentially
more complex in the context of large-scale clinical
applications of ES, and especially WGS [17].
Overall, premature integration of ES/WGS into clinical
care may lead to a cascade effect [18] and strain the
health-care resources in a disproportionate, unjustified
fashion [19]. The immediate, actionable, applications of
the information derived from genomic technologies arelimited at present time [20]. Moreover, approximately
20% of all human genes and, thus, many of the genes
with immediate clinical application have patents on
them [21]. Reporting mutations identified by genome se-
quencing in such genes has not been resolved (e.g. the
Prometheus and Myriad Genetics cases) [22], [23].
It appears that medical genetics is shifting from the
present “phenotype-first” medical model to a “data-first”
model which leads to multiple complexities (see Table 1).
To accelerate the integration of ES/WGS into clinical
practice a substantial shift in thinking is required. This
manuscript outlines a novel approach which can help
address the above-mentioned challenges. The described
“phenotype-first” medical model proposes that ES/WGS
could incrementally be implemented in day-to-day clin-
ical practice in the immediate future, as long as our
focus remains on diseases which, at the time of the
evaluation, have been genetically well characterized.
Discussion
Overview of current clinical genetic practice
In current clinical practice, in order to identify the gen-
etic variant responsible for a patient’s disease, first there
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lowed by molecular testing of a series of relevant gen-
etic loci, individually or in small sets [24]. There exist
a variety of online databases which aim to catalogue
all known diseases with a strong genetic component
(e.g. mendelian genetic syndromes) and link, at least
some of, these diseases to the relevant genes in the
human genome. A very well known example of such a
database which is freely available is OMIM [Online
Mendelian Inheritance in Man; http://omim.org/]. Typ-
ically, to aid in the diagnosis of rare genetic syn-
dromes, a physician would perform a database search
using patient-specific information derived from the
medical evaluation performed in clinic. The clinician
would then verify the search-results and clinically
prioritize genetic testing for the disease that he/she
considers most likely. Clinical genetic tests are often
very expensive, so typically only one gene, or occasion-
ally a group of pre-selected genes typically responsible
for one disease, will be analyzed at a given time. If the
first test is negative, sequential testing of the genes re-
sponsible for the other, less likely but still clinically
suspected, genetic diseases usually follows.
Once a genetic change is identified, the physician eval-
uates the variant for pathogenicity. Some genetic var-
iants can be unequivocally interpreted as pathogenic or
normal variants on the basis of extensive clinical experi-
ence [25]. In other cases, clinical experience is insuffi-
cient and pathogenicity is inferred based on the variants’
predicted effect on protein stability, function, or conser-
vation. Examples of different criteria used in the clinical
interpretation of a genetic variant identified by sequen-
cing include: (1) whether the identified variant has been
listed as a non-pathogenic variant, (2) whether the vari-
ant has been previously reported to cause disease in the
literature and/or databases listing such variants, (3) the
nature of the mutation: e.g. a silent or a nonsense muta-
tion, (4) the position affected and whether this position
is well-conserved across species, and (5) the presence or
absence of the mutation in affected or unaffected family
members. Computational inferences, although very use-
ful, are not always reliable. Clinical experience shows
that even mutations predicted in-silico with high-
confidence to be deleterious may ultimately have no
major consequences [26], [27].
At present, genomic sequencing technologies are
mainly limited to research. They are typically used to
identify the mutant gene which could explain a specific
disease not-yet genetically characterized. Criteria similar
to the ones mentioned above for the interpretation of
clinical test results are used to evaluate the pathogenicity
of the multiple genetic variants identified by ES/WGS
and their possible role in the phenotype under investiga-
tion. ES has proven to be a powerful research toolfor gene discovery in rare monogenic syndromes [for
instance, [28-31]. As the cost of sequencing drops, the
use of WGS is also becoming a research option [32-34].
The genes underlying most unsolved mendelian disor-
ders known will likely soon be elucidated thanks to
ES/WGS.
Individualized Mutation-weighed Phenotype Search
This manuscript proposes a new approach, Individua-
lized Mutation-weighed Phenotype On-line Search
(I-MPOS), which can help properly integrate genomic
technologies in everyday clinical practice in the immedi-
ate future. In the illustrated approach (Figure. 1),
patients have their exome/genome sequenced. The se-
quencing results are stored in an encrypted form on a
platform (such as a chip, a memory key, or stored on a
cloud) and can be accessed via a password only available
to the individual patient. After obtaining authorization,
the clinician can temporarily and anonymously upload
the patient’s encrypted data to a search engine, namely,
Individualized Mutation-weighed Phenotype On-line
Search Engine (I-MPOSE). I-MPOSE simultaneously
operates on the patient’s encrypted data and on a regu-
larly updated database containing selected genetic diag-
noses. Only the diagnoses for which there exists reliable
evidence for a pathogenic relationship with at least one
confirmed relevant region in the human genome and a
well-described, more or less specific, subset of pheno-
typic characteristics are included in the database.
I-MPOSE identifies the genetic changes present in the
patient’s sequenced encrypted genome relative to the
reference genome and assigns a weight score to each of
them based on predetermined criteria integrated in the
search algorithm. The pre-set criteria evolve as new
knowledge is acquired and are equivalent, at any time, to
the criteria used in the clinical evaluation of variants
identified after a clinical genetic test (please refer to
Figure. 2 for some examples based on current practice).
The overall impact score calculated for each genetic
variant identified corresponds to the level of certainty
for its pathogenicity. The implementation of this ap-
proach can take advantage of the numerous databases
and tools currently used in the interpretation of genetic
variants generated by clinical genetic testing or ES/
WGS clinical research (Figure. 3).
For this method to be most useful, the database has to
include all known diseases which have been both pheno-
typically and genetically well characterized, at any given
time, and be regularly updated based on research find-
ings and clinical experience. Searching this database
while taking into consideration both the patient’s pheno-
type and his/her entire genomic data when ranking the
results could aid enormously in the medical genetic
evaluation of patients (please refer to discussion below).
Figure 1 Schematic overview of I-MPOS, the new clinical genetic approach proposed. Patients have their exome/genome sequenced and
their encrypted data stored on a password-protected platform which remains at the disposal of the individual patient. A patient presents to clinic
with a specific medical concern. The physician performs a clinical evaluation and identifies some important features (“phenotype-first” approach).
He or she then performs a database search using keywords related to the clinically assessed phenotype, as presently done, thereby providing an
initial ranking of possible genetic diseases. This initial ranking is then adjusted by I-MPOSE based on the weight scores automatically assigned to
the mutations identified by ES/WGS in the patient’s genes/loci known to be linked to each genetic disease; thus providing a second ranking of
the possible genetic diseases. I-MPOSE simultaneously operates on the patient’s encrypted data and on a regularly updated database containing
all well characterized genetic diagnoses. It is run during every clinical visit so as to incorporate new findings from clinical evaluation, as well as,
new genetic knowledge incorporated in the regularly updated database.
Trakadis BMC Medical Genomics 2012, 5:31 Page 4 of 11
http://www.biomedcentral.com/1755-8794/5/31In summary, the patient presents to clinic with a specific
medical concern. As currently practiced, the physician
performs a clinical evaluation and identifies some im-
portant features (“phenotype-first” approach). He or she
then performs a database search using keywords related
to the clinically assessed phenotype, as presently done,
thereby providing an initial ranking of possible genetic
diseases. This initial ranking of possible genetic diseases
is then adjusted by I-MPOSE based on the assigned
weight scores for the variants identified by exome/gen-
ome sequencing in this patient; thus providing a second
ranking of possible genetic diseases based on the said
adjustment.
Given that the patient’s personal genome data is
encrypted, the physician does not yet know anything
about the exact mutations identified by genome/exome
sequencing of the patient evaluated. However, afterviewing the adjusted ranking results, the physician could
provide counselling to the patient and obtain informed
consent to have access to the genomic data at the spe-
cific locus of interest before sending a sample for clinical
genetic testing to confirm the diagnosis.
EXAMPLE
A patient P referred to genetics for hypotonia suffers
from Smith Lemli Opitz (SLO) syndrome. The patient
P’s exome has been sequenced. According to the crude
data from exome sequencing, patient P has a homozy-
gous mutation, in the DHCR7 gene, known to cause
SLO. The patient is clinically evaluated by a medical
geneticist following exome sequencing. The geneticist is
not aware of the mutation in the DHCR7 gene nor that
the patient has SLO syndrome. The only positive indica-
tions the geneticist identifies as important during the
Figure 2 Examples of factors to be taken into consideration when calculating a variant’s “weight”. An overall score is automatically
calculated by I-MPOSE for each variant identified with ES/WGS by simultaneously taking into consideration different factors. Some examples of
such factors are listed above in Figure. 2. Information about the pattern of inheritance can also be factored in the weight assignment process
(Figure.2b). The overall score corresponds to the level of certainty for the pathogenicity of each genetic variant identified. An option to allow for
adjusting the default parameters is possible through an interactive checklist. The physician can opt to assign a different contribution for a specific
parameter (e.g. a much increased contribution for homozygosity when dealing with consanguinity) in the calculation of the variant’s overall score.
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eticist performs two searches, a standard search as well
as a search with I-MPOSE. The standard search is per-
formed on the previously-mentioned website, OMIM
[http://omim.org/].
The OMIM search results for the keywords “hypotonia
AND heart defect” garnered 175 hits. SLO based on the
search terms had a match score (Y) and was ranked #23
on this list. The I-MPOSE search was also performed on
the OMIM website in tandem in conjunction with the
patient’s encrypted sequencing data. The geneticist didnot look at the ES data per se. He/she simply ran during
the search in tandem with the clinical criteria “hypotonia
AND heart defect” the ranking system previously
described, which took into consideration the automatic-
ally assigned impact score of each variant identified by
ES. Given that the identified pathogenic mutation in
DHCR7 was assigned by I-MPOSE a high impact score
(e.g. X), this time the cumulative score of SLO (Y x X)
was relatively higher than that of most other diseases on
the list. Hence, SLO was ranked higher on the search
results list and the geneticist entertained the diagnosis of
Figure 3 Examples of ongoing projects & tools illustrating that the necessary infrastructure for I-MPOSE is already available. Some
examples of existing databases for human disease and genetic variation, as well as, tools available for the annotation of variants identified by
ES/WGS.
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clinical testing to confirm the diagnosis. In this example,
as per current practice, before undertaking clinical mo-
lecular testing the geneticist could have chosen to send a
less-expensive non-genetic lab test named a sterol pro-
file, which if positive would have further increased the
physician’s a priori suspicion for SLO. Similarly, the
physician, after discussing his suspicion of SLO syn-
drome with the patient (or the family of the patient as
appropriate), could have obtained consent to specifically
analyze the patient’s encrypted exome sequencing data
in the DHCR7 gene locus. This analysis could beperformed in collaboration with the clinical molecular
lab director before ultimately pursuing the clinical diag-
nostic test. A more careful analysis of the changes iden-
tified by ES/WGS in this locus would have thus
provided further evidence to support that the diagnosis
of SLO syndrome needed to be entertained.
Clinical Implications
Conventional approaches often require multiple genetic
tests before a molecular diagnosis is reached and each
clinical genetic test is often very expensive. The proposed
approach, which follows the existing “phenotype-first”
Table 2 Benefits of the I-MPOS approach
-Simplification of pre-test counselling, informed consent and post-test
counselling
-Protection of the patient’s privacy and autonomy
-Genomic sequencing, even during newborn period, practical, ethical
and clinically useful
-Increased diagnostic yield; cost-effective approach; decreased time to
diagnosis
-Overcomes challenges such as shortage of personnel, the management
of the huge amount of data generated, incidental findings, VUS, and
duty to re-contact.
-Incremental integration of genomic technologies into clinical practice.
-Standardized approach in medical genomics, even where resources are
limited
-Promotion of genomic research
-Refinement of clinical phenotype: partial matches for known
syndromes; biochemical phenotypes
-Prevents over-medicalization of genomic data while enabling serving
the patient’s concerns
-Progressive education of both the health care personnel and the
general public regarding personalized/preventive medicine
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genes to be tested in a clinical lab and is overall efficient
from a resource, time and personnel point of view both
in the clinic and the laboratory.
Based on the lessons learned from the past [35,36], an
evidence-based, cautious approach to genomic medicine
will be more efficient than premature efforts to integrate
these technologies into clinical practice [5]. The I-MPOS
approach allows ES/WGS to be used as a screening test
rather than a clinical diagnostic test. A confirmatory
clinical diagnostic test is still required, thus at least tem-
porarily addressing the issue of patented genes, while en-
suring reliable test results. The object of this method is
to increase the diagnostic yield of a clinical evaluation in
a cost-effective fashion and to decrease the time to diag-
nosis. For the remaining unresolved cases, the clinician
needs to resort back to conventional approaches, which
reduces false negatives, as well as, accounts for other
known genetic explanations (e.g. epigenetic changes) not
accounted for by ES/WGS. The clinician remains re-
sponsible for identifying and clinically prioritizing testing
for the clinically suspected syndromes using the whole
spectrum of clinical genetic testing modalities available.
I-MPOSE is, simply, an additional tool at the clinician’s
disposal to make the foregoing assessment. Its limita-
tions are minimized as long as qualified medical geneti-
cists perform the evaluation, at least in the early stages
of medical genomics, until other health professionals are
adequately educated regarding its value, limitations, and
appropriate clinical use.
In practice, the clinician does not have access to the
patient’s genome/exome sequencing results. The results
remain encrypted and password-protected so that the
patient retains full control over his/her data and how it
is utilised. The patient only needs to consent that the
clinician can explore the genetic causes which can po-
tentially explain the specific phenotype/medical-issue at
hand. The clinical terms entered in a search are selected
based on the diseases of interest for which the family is
seeking medical advice. Patients whose diagnosis has not
been made will be seen in follow-up, as per present
practice, and I-MPOSE will be run during every clinical
visit so as to incorporate new findings from clinical
evaluation, as well as, new genetic knowledge incorpo-
rated in the regularly updated database (Figure.1 for dia-
gram). Hence, I-MPOS addresses many of the challenges
associated with integrating genomic technologies into
clinical practice (see Table 2).
Some individuals are likely to want to learn more from
their genomic data as soon as ES/WGS is performed
and this could be available in private, if properly regu-
lated. However, in most centers, investing financial
recourses for such services would place pressure on an
already strained health-care system [37,38]. Until theorganisational, ethical, legal, and social issues are prop-
erly addressed, and the clinical validity/utility, as well as,
the cost-effectiveness of such findings are proven, the
clinician’s access to the raw data will be restricted to rare
challenging cases in a research setting. Hence, the I-
MPOS paradigm helps to standardize care in the field of
medical genomics based on realistic expectations which
evolve as new knowledge is acquired, thus progressively
increasing the quality of care provided to patients. Ini-
tially benefits will mostly focus on exome sequencing
and rare mendelian conditions frequently encountered
by clinical geneticists. The widespread utilization of ES/
WGS will subsequently provide us lessons about more
complex diseases.
Databases with patient-specific genomic data can store
information of patients who decide to have their data
stored for future reference or research. These databases
will be managed similarly to the guidelines for “bio-
banks”. With this approach, anonymized exome sequen-
cing data from a great number of consenting individuals
will likely be available and help us advance our know-
ledge of clinical application of genomic technologies. At
a clinical level, on top of enabling earlier diagnosis [39],
I-MPOS will aid in the refinement of the phenotype of
known syndromes. For example, in conventional
approaches only patients who fit very closely all or al-
most all characteristics of a described genetic syndrome
are tested for the genes involved. The proposed ap-
proach provides for the partial matches of patients to be
identified and their characteristics to enrich and refine
the spectrum of clinical characteristics of any given
syndrome.
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The most central components needed for I-MPOS to be
successfully implemented are the availability of well
curated databases and the reliability of the “impact
score” assignment for each variant identified. To aid in
the latter, multiple computational tools exist (some of
which are listed in Figure.3). There are also software
tools which enable the user to take advantage of a gene
filter (e.g. based on quality score, pathway, gene-
ontology, OMIM information) and different biological
databases when performing the functional annotation.
One such example is the Sequence Variant Analyzer
(SVA), which is also allowing users to explore the
strength of the associations of identified variants with
studied traits [40].
As previously stated, computational predictions about
the pathogenicity of variants are not always reliable.
However, combining the results of different such meth-
ods, as well as population and/or family-based data
about the cosegregation of the variant with disease,
using different statistical methods can be helpful in the
calculation of an “overall impact-score” which is more
reliable. For instance, Bayesian analysis can be used to
factor in results of different computational tools in the
overall score. Moreover, relative risk analysis and/or
Transmission Disequilibrium Test (TDT) analysis for
each variant at a population or family level can also be
very useful in predicting a variant’s pathogenicity, par-
ticularly when ES/WGS usage becomes wide-spread [41-
44]. Freely available statistical software like Family Based
Association Test, a.k.a. FBAT, can be useful to this end
[45]. In the future, the combination of different bioinfor-
matics and statistical tools will be incrementally more
important in the calculation of the “impact score” of
each variant. It is also possible that metabolomics will
lead to the identification of specific metabolic profiles/
signatures associated with specific variants and that the
(degree of ) biochemical imbalance will constitute an im-
portant factor in predicting the pathogenicity, and thus
in calculating the variant’s “impact factor”. There are
already projects in metabolomics which in the future
could be useful to this end [46-48].
In the first steps of the I-MPOS endeavor, though, one
needs to be particularly cautious and focus on variants
known to be pathogenic based on clinical experience.
Already existing guidelines for variant interpretation can
be used to classify each variant identified in one of four
or six different groups with a different “impact factor”
potentially assigned to each group [49,50]. Alternatively,
initially the data of already existing databases listing anno-
tated variants and classifying them as pathogenic or not
can be the only factors included in the score assignment.
Worldwide, ongoing efforts already aim to create compre-
hensive collections of validated associated variants, asillustrated in Figure.3. Potentially useful curated databases
include the Human Gene Mutation Database (HGMD)
[51], Diagnostic Mutation Database (DMuDB) [52], Muta-
Database [53], and the ClinVar database [54,55]. The imple-
mentation of common methods and clinical standards for
data collection and reporting are of great importance for
the optimal operation of I-MPOSE. The interpretation of
genomic information will change over time as new risks are
identified and others are refuted. Hence, the database to be
used will need to be updated regularly with all the genetic
changes confirmed based on research and clinical experi-
ence to cause or predispose to a genetic disease/phenotype.
With regards to phenotypic data, an interface with freely
available or private databases (such as OMIM, Genere-
views, London Medical Databases, or Possum Web) will
be needed [56-59]. In order for the search to be optimized,
a standardized vocabulary of phenotypic abnormalities
encountered in human disease and the semantic relation-
ships between them will be important. The Human Pheno-
type Ontology (HPO) and Phenomizer could be very
useful to this end [60].
In the future, it would be useful if the database used
for I-MPOSE included genes sorted into “priority tiers”
based on the evidence of involvement in each genetic
disease (“informatics disease panels” [61]). This could be
expanded to include prioritization of genes involved in
specific sub-phenotypes (rather than the genetic disease
as an entity) like “microcephaly”, “short stature” or even
more complex phenotypes such as biochemical profiles.
In brief, illnesses, like schizophrenia or Type 1 Diabetes
[62-66], with high heritability but complex inheritance,
may be shown in the future to constitute a constellation
of different pathogenetic processes leading to a similar
phenotype. Some of these pathogenetic processes may
ultimately have a specific signature not only at the level
of the genome, but also at the level of the epigenome,
transcriptome or metabolome. If the known such signa-
ture profiles are listed in the databases used by I-
MPOSE, the data generated at the time of the clinical
evaluation from RNA sequencing [67-69] and/or meta-
bolomic profiling [70,71] or even epigenomic changes
[72] over time in such a (symptomatic) patient could
serve as a phenotypic trait refining the search.
The concept of “informatics disease panels” can also
help in the identification of novel genes contributing to
known genetic diseases/phenotypes. One can use differ-
ent methods (see [73-82] for examples) to select candi-
date genes for each genetic disease/phenotype and also
include them in the database, albeit with a lower “prior-
ity”, representing the amount of evidence/probability of
the gene’s involvement in the respective genetic disease.
For any given patient, when a phenotype is ranked
highly after I-MPOSE search but no mutations are found
in all genes documented to cause the disease, consent to
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type at hand for mutations could be obtained.
In conclusion, the widespread utilization of ES/WGS
will subsequently provide us lessons about complex gen-
etic diseases. The weight factors and the assigning
process will evolve based on emerging knowledge (e.g.
to account for gene-gene or gene-environment interac-
tions in complex diseases [83-89]). As research and gen-
etic knowledge advance, the benefits of this approach
will increase exponentially. I-MPOS could ultimately
help cautiously drive the paradigm shift to personalized
healthcare and eventually preventive medicine.
Summary
This is an exciting time for medicine: the era of genomic
medicine. However, the implementation of ES/WGS in
clinical practice should only take place when the chal-
lenges posed by ethics and policy issues have been
addressed. Unfortunately, it is very likely that the fast
pace of development of these technologies and their
ability to facilitate diagnosis, to reduce the incidence of
deleterious genetic disorders, and to inform therapy will
lead to their premature introduction in clinic [90]. As
previously discussed, the era of WGS is just around the
corner [91]. Already ES is employed by some direct-to-
consumer genetic testing companies [19,92]. We now
need to prepare the framework required for responsible
and successful integration of ES/WGS in patient care;
thus ensuring the appropriate and effective usage of gen-
omic information [91]. It is widely recognized that auto-
mated systems and clear guidelines will be necessary in
this process. Our current approaches need to be reas-
sessed but not changed solely based on the availability of
a new technology. For instance, currently genetic risk as-
sessment for individuals who are not at increased risk
based on family history or clinical presentation is gener-
ally restricted to newborn screening programs meeting
specific criteria [5,93]. Is there adequate evidence to sug-
gest that a departure from these standards will be bene-
ficial to society? It appears that medical genetics is
shifting from the present “phenotype-first” medical
model to a “data-first” model which leads to multiple
complexities. This manuscript discusses a “phenotype-
first” approach, namely, Individualized Mutation-
weighed Phenotype Search (I-MPOS), which could
potentially render widespread use of ES/WGS, in the
immediate future, practical, ethical and clinically useful.
The proposed approach allows for a more efficient
prioritization of the genes to be tested in a clinical lab
based on both the patient’s phenotype and his/her entire
genomic data. I-MPOS protects the patient’s privacy and
autonomy and enables an incremental integration of
genomic technologies into clinical practice. It allows for
progressive education of both the health care personnel,including medical geneticists and clinical laboratory
scientists, and the general public regarding personalized/
preventive medicine. The I-MPOS approach ensures that
we do not over-medicalize genomic data but rather con-
tinue our current medical model which is based on serv-
ing the patient’s concerns. Service should not be solely
driven by technology but rather by the medical needs
and the extent to which a technology can be safely and
effectively utilized.
The era of genomic medicine is already a reality.
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